Clik here to view.
CANbridge Pharmaceuticals CAN103 Investigational New Drug Application...
BEIJING & CAMBRIDGE, Mass. CANbridge Pharmaceuticals Inc., a leading China-based global rare disease-focused biopharmaceutical company committed to the research, development and...
View ArticleClik here to view.
Propanc Biopharma Appoints Paul Patrizio as Strategic Advisor to Establish US...
MELBOURNE, Australia Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and...
View ArticleClik here to view.
PierianDx完成高达4,750万美元的成长资本融资
圣路易斯 (美国商业资讯)–临床基因组学知识的全球领导者PierianDx宣布，该公司已完成3,000万美元的新一轮成长资本融资，包括股权融资和一项定期贷款便利，包括在特定条件下，到2022年和2023年获得高达1,750万美元的额外款项。此次融资由医疗保健投资公司OrbiMed领投，现有投资者Health Catalyst Capital、Research Triangle...
View ArticleClik here to view.
Clik here to view.
BeiGene to Present Clinical Data on BRUKINSA in Chronic Lymphocytic Leukemia...
CAMBRIDGE, Mass. & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment...
View ArticleClik here to view.
EdiGene to Present Latest Research on A Novel Surface Marker and Migration...
BEIJING & CAMBRIDGE, Mass. EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases...
View ArticleClik here to view.
HitGen and Cambridge Molecular announce a strategic partnership, bringing...
CHENGDU, China & CAMBRIDGE, England HitGen Inc. (688222.SH) and Cambridge Molecular are pleased to announce an exclusive alliance, introducing DeepDELve 2 – Cambridge Molecular’s highly...
View ArticleClik here to view.
AVROBIO to Present Clinical and Preclinical Data at the 14th ICIEM Conference
CAMBRIDGE, Mass. AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that it will present...
View ArticleClik here to view.
EdiGene Enters Research Collaboration with the University of...
BEIJING & CAMBRIDGE, Mass. EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases...
View ArticleClik here to view.
RIBOMIC Announces RBM-007 Phase 1 Clinical Trial Results for Achondroplasia
TOKYO RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TYO:4591), announced the results from its Phase 1, healthy volunteer clinical study using RBM-007...
View ArticleClik here to view.
BeiGene Initiates First-in-Human Phase 1 Clinical Trial of Investigational...
CAMBRIDGE, Mass. & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines, today announced that the...
View ArticleClik here to view.
卡弗里基金会设立两个卡弗里伦理、科学和公众中心，鼓励公众参与探讨科学发现所带来的伦理问题
洛杉矶 (美国商业资讯)–科学发现加深了我们对自然和自身的理解，有可能改变我们的日常生活，但也会给社会带来伦理问题或风险。 本新闻稿包含多媒体。此处查看新闻稿全文： https://www.businesswire.com/news/home/20211213005480/zh-CN/ Brooke Smith, Director of Public Engagement, The Kavli...
View ArticleClik here to view.
カブリ財団が倫理、科学、公共を研究する2つのセンターを開設し、科学的発見から生じる倫理的影響を探求する上で一般市民の関与を促進
ロサンゼルス （ビジネスワイヤ） — 科学的発見は自然と人類に対する理解を深め、日々の生活に変化を与える可能性を持つと同時に、倫理上の懸念や社会へのリスクをもたらし得るものでもあります。 本プレスリリースではマルチメディアを使用しています。リリースの全文はこちらをご覧ください。：https://www.businesswire.com/news/home/20211213005482/ja/...
View ArticleClik here to view.
Takeda Drives Continued Scientific Leadership Through Real-World Evidence in...
CAMBRIDGE, Mass. Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”) today announced the presentation of nine company-sponsored abstracts at the 63rd American Society of Hematology...
View ArticleClik here to view.
Numab and 3SBio’s Sunshine Guojian Expand Partnership to Develop Novel T Cell...
WÄDENSWIL, Switzerland, SHENYANG, China, & SHANGHAI Numab Therapeutics AG (Numab) and 3SBio Inc. (“3SBio”, HKEX:1530) announced today that 3SBio’s subsidiary Sunshine Guojian Pharmaceutical...
View ArticleClik here to view.
Provectus Algae Moves Sustainable Synthetic Biology Biomanufacturing Platform...
NOOSAVILLE, Australia Provectus Algae (Provectus), an Australian synthetic biology company specializing in biomanufacturing to produce specialty ingredients for a wide array of industries and...
View ArticleClik here to view.
BostonGene and NEC Announce Global Partnership
TOKYO & WALTHAM, Mass. BostonGene Corporation and NEC Corporation (NEC; TSE: 6701) today announced a strategic global partnership agreement that will enable the companies to offer BostonGene...
View ArticleClik here to view.
Inventia Life Science Accelerates Growth with $25M Series B and Launches 3D...
SYDNEY Inventia Life Science, a world leader in advanced 3D cell cultures for research and clinical purposes, has today announced the close of a US $25M Series B funding round, led by Blackbird...
View ArticleClik here to view.
Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to...
SOUTH SAN FRANCISCO, Calif. Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and...
View ArticleClik here to view.
Takeda Receives Positive CHMP Opinion for Vedolizumab IV for the Treatment of...
OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
View Article